avosentan
- CAS No.
- 290815-26-8
- Chemical Name:
- avosentan
- Synonyms
- CS-644;SPP-301;avosentan;Ro 67-0565;Avosentan (SPP301);RO 67-0565; SPP-301;Avosentan (Ro 67-0565;avosentan,CID 9912992;Avosentan, 10 mM in DMSO;inhibit,SPP 301,Inhibitor,Avosentan,SPP301,Endothelin Receptor
- CBNumber:
- CB41508589
- Molecular Formula:
- C23H21N5O5S
- Molecular Weight:
- 479.51
- MDL Number:
- MFCD23843806
- MOL File:
- 290815-26-8.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Boiling point | 575.5±60.0 °C(Predicted) |
|---|---|
| Density | 1.363 |
| storage temp. | Store at -20°C |
| solubility | DMSO : 6.67 mg/mL (13.91 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| form | Powder |
| pka | 3.19±0.10(Predicted) |
| color | White to off-white |
| FDA UNII | L94KSX715K |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P330-P501 |
avosentan price More Price(38)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Usbiological | 002983 | Avosentan | 290815-26-8 | 10mg | $531 | 2026-06-03 | Buy |
| Biosynth | QLA81526 | Avosentan | 290815-26-8 | 25mg | $742.25 | 2026-06-04 | Buy |
| Biosynth | QLA81526 | Avosentan | 290815-26-8 | 50mg | $1187 | 2026-06-04 | Buy |
| Biosynth | QLA81526 | Avosentan | 290815-26-8 | 100mg | $1899 | 2026-06-04 | Buy |
| ChemScene | CS-0625 | Avosentan 98.15% | 290815-26-8 | 5mg | $103 | 2026-06-04 | Buy |
avosentan Chemical Properties, Uses, Production
Uses
Avosentan is a competitive antagonist of Endothelin-1 (ET-1) with a high selectivity for the ETA receptor. Avosentan may be a potential option in the treatment of glaucoma.
Enzyme inhibitor
This potent, selective and orally available endothelin A receptor blocker (FW = 479.51 g/mol; CAS 290815-26-8; Soluble in DMSO), also known by its code names SPP301 and Ro 67-0565, induces the dose-dependent reduction in the fractional renal excretion of sodium (up to 8.7% at 50 mg avosentan), with a paralleled dose-related increase in proximal sodium reabsorption. Avosentan reduces albuminuria, when added to standard treatment in patients with type 2 diabetes and overt nephropathy, but induces significant fluid overload and congestive heart failure.
avosentan Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| J & K SCIENTIFIC LTD. | 18210857532 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| LGM Pharma | 1-(800)-881-8210 | inquiries@lgmpharma.com | United States | 2110 | 70 |
| Chemsky (shanghai) International Co.,Ltd | 021-50135380 | shchemsky@sina.com | China | 15350 | 60 |
| Haoyuan Chemexpress Co., Ltd. | 021-58950125 | info@chemexpress.com | China | 7545 | 61 |
| MedChemexpress LLC | 021-58955995 | sales@medchemexpress.cn | United States | 4853 | 58 |
| AdooQ BioScience, LLC | +1 (866) 930-6790 | info@adooq.com | United States | 2774 | 58 |
| Qingdao Kingway Pharmtech Co., Ltd. | 0532-87118899 | sales@kingwaypharm.com | China | 119 | 56 |
| Hubei XinyuanShun Chemical Co., Ltd. | 13971561712, 13995564702, 027-50664929 | hbeixys2001@163.com | China | 3110 | 55 |
| HangZhou YuHao Chemical Technology Co., Ltd. | 0571-82693216 | info@yuhaochemical.com | China | 1999 | 58 |
